Nasen Odt (Zolpidem Tartrate)

Zolpidem Tartrate, the active ingredient in Nasen Odt, is a non‑benzodiazepine hypnotic presented as an orally disintegrating tablet for oral use. It treats insomnia characterized by difficulty initiating sleep in adult patients.

GNH USA supplies Nasen Odt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Zolpidem Tartrate is indicated for sleep‑related disorders, primarily acting on the central nervous system to facilitate sleep onset.

- Insomnia (difficulty initiating sleep): helps patients fall asleep faster. - Primary insomnia: promotes sleep initiation in adults with chronic insomnia. - Sleep onset disorder: facilitates quicker transition to sleep.

Zolpidem Tartrate may cause a range of adverse reactions, ranging from mild to serious.

Common Side Effects: - Drowsiness - Dizziness - Headache - Dry mouth - Nausea - Unpleasant taste

Serious or Rare Side Effects: - Complex sleep behaviors (e.g., sleepwalking) - Allergic reactions (rash, swelling) - Hallucinations or delusions - Depression or suicidal thoughts - Respiratory depression

Before prescribing Zolpidem Tartrate, clinicians should evaluate the patient's sleep disorder and overall health status.

- Assess sleep disorder: confirm diagnosis of insomnia. - Avoid concurrent CNS depressants: limit use with alcohol or opioids. - Use lowest effective dose: start with the minimal dose required for efficacy. - Hepatic impairment: adjust use in patients with severe liver disease. - Pregnancy: avoid use when pregnancy status is unknown or confirmed. - Store at ambient temperature: keep in the original pack, protect from moisture.

Zolpidem Tartrate can interact with other medications, affecting its safety and efficacy.

Major Interactions (Avoid): - Alcohol: may potentiate sedation and respiratory depression. - Opioids: combined use increases risk of profound CNS depression. - Other sedative‑hypnotics: additive sleep‑inducing effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase zolpidem plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce zolpidem effectiveness.